Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Addiction. Author manuscript; available in PMC 2010 May 1.
Published in final edited form as:
PMCID: PMC2777686

Patterns of change in withdrawal symptoms, desire to smoke, reward motivation, and response inhibition across three months of smoking abstinence



We have previously demonstrated that acute smoking abstinence is associated with lowered reward motivation and impaired response inhibition. This prospective study explores whether these impairments, along with withdrawal-related symptoms, recover over three months of sustained abstinence.


Participants completed a 12-hour abstinent baseline assessment and were then randomly allocated to quit unaided or continue smoking. All were re-tested after 7 days, 1 month and 3 months. Successful quitters’ scores were compared with those of continuing smokers, who were tested after ad libitum smoking.


Goldsmiths, University of London.


33 smokers who maintained abstinence to 3 months, and 31 continuing smokers.


Indices previously demonstrated in this cohort of smokers to be sensitive to the effect of nicotine vs. acute abstinence: reward motivation (SHAPS, CARROT, Stroop); tasks of response inhibition (antisaccade task; CPT) and clinical indices of mood (HADS), withdrawal symptoms (MPSS) and desire to smoke.


SHAPS anhedonia and reward responsivity (CARROT) showed significant improvement and plateaued after a month of abstinence, not differing from the scores of continuing smokers tested in a satiated state. Mood, other withdrawal symptoms and desire to smoke all declined from acute abstinence to 1 month of cessation and were equivalent, or lower than, the levels reported by continuing, satiated smokers. Neither group showed a change in CPT errors over time whilst continuing smokers, but not abstainers, showed improved accuracy on the antisaccade task at 3 months.


Appetitive processes and related affective states appear to improve in smokers who remain nicotine-free for 3 months whereas response inhibition does not. Although in need of replication, the results tentatively suggest that poor inhibitory control may constitute a long-term risk factor for relapse and could be a target for intervention.


Acute abstinence from regular smoking is associated with somatic symptoms, low mood [1,2] motivational and cognitive disturbance [3-7] and impaired inhibitory control [8-10]. Which of these dysfunctions develop as a consequence of smoking, or are constitutional deficits that predate regular smoking, remains uncertain. If the former is the case, and if neuroadaptations are reversible, then such impairments should normalise with continuing abstinence; if the latter is the case, they would not be expected to improve even with protracted abstinence. Since the time course and trajectory of such impairments may affect the ability of the smoker to maintain abstinence, it is useful to chart their natural history.

Very few prospective studies have included measures of cognition. In one recent study in which mental arithmetic was assessed post-cessation [11], scores returned to baseline (pre-quit) levels within ten days of quitting. However, Gilbert and colleagues [12] noted reduced accuracy on the rapid visual information processing (RVIP) task and EEG deactivation in abstinent smokers which failed to return to either pre-quit baseline, or smoking control levels after 31 days.

A handful of cross-sectional studies have compared current, ex, and non-smokers on indices of reward motivation and cognition; in some, impairments were demonstrated by current smokers but not ex-smokers [13, 14], whilst in others the opposite was found [15]. Whilst this may reflect the particular tests used, a recent EEG study [16] found hypoactivation of the pre-frontal cortex and anterior cingulate in smokers who had been abstinent for a mean of 11 years.

With respect to abstinence-related affective and somatic symptoms, nicotine withdrawal is characterised by anxiety, depression, irritability, restlessness, difficulty concentrating and desire to smoke [1,2]. Early studies suggested that such symptoms recover within a few weeks [17-19]; however, reported durations in recent studies have ranged from less than two weeks [20,11] to over a month [21-23]. In one of very few studies which have tracked withdrawal symptoms for longer periods, Piasecki and colleagues [24,25] found considerable heterogeneity in the profiles of symptoms presented by different individuals (75% of whom used a nicotine patch), and approximately 40% showed an increase in the severity of withdrawal symptoms after 30 days of abstinence, [24]. In a related study they found comparable levels of depression, anhedonia and somatic features (e.g. decreased appetite, lack of motivation, impaired sleep) in both current and ex-smokers (abstinent for at least 6 months) relative to never-smokers [25].

Prospective studies exploring the time course of abstinence-related responses are, however, methodologically complex [26,22]; a major weakness is selective dropout which can seriously bias conclusions. For example, high relapse rates may distort mean scores in the residual sample if relapse is more likely in those who experience the greatest severity of symptoms or cognitive impairment in the early stages of abstinence. Relatedly, successful abstainers may be characterised by atypical levels of motivation, or may differ in other important ways from the broader population of smokers; hence their experience may not generalise to all smokers. In studies which lack a randomly assigned ‘continuing-to-smoke’ control group, the interpretation of findings may be limited by practice or familiarity effects.

The present study explored changes in withdrawal symptoms, mood, reward motivation and response inhibition over 3 months of continuous smoking abstinence, comparing smokers randomly allocated between ‘quit’ and ‘continue-to-smoke’ conditions.



Smokers were recruited through adverts in local newspapers, radio stations, colleges, libraries and pharmacies in the South East London area. All were aged between 18 and 65 and smoked ten or more cigarettes a day and within the first hour of waking. Exclusion criteria included current diagnosis of psychiatric or neurological condition, regular use of prescription or class A recreational drugs, and pregnancy. All participants gave written informed consent and the study was approved by Goldsmiths Ethics Committee.

Design & Procedure

This was part of a larger study [5,8]. 145 smokers (57% female; 78% Caucasian) were assessed on two occasions after overnight (12 hour) abstinence (confirmed by breath CO levels < 11ppm), once after receiving a 4-mg NiQuitin lozenge and once after receiving a placebo lozenge (order counterbalanced; procedure double-blind).

Immediately after the second session participants were randomly allocated in a 3:1 ratio between ‘quit’ and ‘continue-to-smoke’ conditions. Those in the quit group were provided with written information and advice but were prohibited from using NRT or other medications. Assessments were repeated at 7 days, 1 month and 3 months, and any quitters who reported more than one lapse since the last session or who had a salivary cotinine level of more than 20 ng/ml were classified as relapsers. Participants allocated to the ‘continue to smoke’ condition were required to smoke a cigarette just before each follow-up testing session to ensure that they were tested in a satiated state.

All participants were offered incremental financial incentives for participating in each successive assessment, subject to their compliance with the requirement to remain abstinent or continue smoking. Participants did not receive any payment until their final assessment. The maximum payment was £150 for those who attended all 5 sessions.

Assessment measures

Demographic information included age, gender, and years of education.

Baseline smoking-related measures

  • Cigarettes smoked per day (self-report)
  • Salivary cotinine: Participants provided a saliva sample at a pre-test screening session and at each follow-up. A cut-off of 20 ng/ml was used for verification of non-smoking status [27].
  • The Fagerström Test of Nicotine Dependence (FTND) [28]: a six-item self-report scale to assess nicotine dependence. Scores range from 0 (low dependence) to 10 (high dependence).

Clinical variables measured at baseline and each follow-up
  • The Hospital Anxiety and Depression Scale (HADS) [29] assesses self-rated anxiety and depression over the preceding 7 days. Total scores range from 0 to 21 for both states.
  • Desire to smoke: Participants rated their response to the question ‘how strong is your desire to smoke right now? From 1 = not at all strong to 7 = extremely.
  • Mood and Physical Symptoms Scale (MPSS) [30]: Participants rated the severity of 7 withdrawal-related symptoms on a 0−4 scale ‘at this moment in time’. The maximum score of 28 indicates severe symptoms.

Experimental measures assessed during acute abstinence and at each follow-up

The full assessment battery is detailed in Dawkins et al. [5]. Here we focus on only those indices found in the full sample to be impaired during acute abstinence (i.e. in the placebo relative to the nicotine lozenge condition). Specifically:

Reward Motivation
  • The Card Arranging Reward Responsivity Objective Test (CARROT) [3]. Participants are required to sort cards according to a simple rule under conditions of financial reward (R) and no reward (NR) presented over 3 experimental trials in the order NR1, R, NR2. The ‘reward responsivity index’ (RRI), impaired during abstinence,[5] is the average card sorting rate (cards per second) under NR subtracted from the average card sorting rate under R.
  • Anhedonia: The Snaith-Hamilton pleasure scale (SHAPS) [31] is a 14-item self-report scale measuring hedonic tone. Total score ranges from 0 (not anhedonic) to 42 (highly anhedonic).
  • Attentional bias to reward cues (modified Stroop) [6]. Participants colour-name the ink in which each of 88 words (either neutral or pleasure-related; order counterbalanced) are printed. The neutral words serve as a comparison against which to evaluate the interference from the pleasure-related words. Abstinence reduces bias towards pleasure-related relative to neutral words as reflected in number of errors [5]. The ‘pleasure bias’ index is errors to pleasure-related words minus errors to neutral words; we previously found the effect of acute abstinence to affect this error index and not the overall speed of colour-naming (see Dawkins et al., [5]).

Response Inhibition
  • Oculomotor antisaccade accuracy [32,33]. Participants are required to suppress a reflexive glance towards a peripherally-appearing stimulus and instead generate an eye movement (antisaccade) in the opposite direction. The index impaired during acute abstinence [7] and therefore analysed here, is percentage correct.
  • Motor errors in the Continuous Performance Task (CPT) [34]. 5-digit numbers are presented visually at a constant rate of two per second for five minutes. Experimental stimuli (sequences with no obvious structure, e.g. 97528) are separated one from the next by three ‘filler’ stimuli of the fixed sequence 12345. Participants are required to press a button when two consecutive experimental stimuli are identical, and not to press the button in response to filler stimuli. Acute abstinence was associated with a higher number of commission errors to filler stimuli (‘CPT motor errors’) [7].

Statistical analysis

Each variable was subjected to repeated measures ANOVA with the between-subjects factor of GROUP (abstainers vs. continuing smokers) and the within-subjects factor of OCCASION (acute abstinence as assessed in the baseline placebo lozenge condition; 7 days; 1 month; 3 months). Thus whilst both groups were in the same 12-hour abstinent state at baseline, in subsequent assessments the continuing smokers were nicotine satiated having smoked immediately prior to the assessment session whilst the quit group were completely nicotine free. Since we were specifically interested in comparing the two groups’ patterns of change from one occasion to the next, a priori contrasts compared scores at adjacent time points (i.e. baseline vs. one week; one week vs. one month; one month vs. three months). Where relevant, post-hoc t-tests were also used to compare groups at specific time points, to supplement these contrasts.

Given the high rate of relapse in the quit group (see below) which begins to undermine the initial effects of randomization, we have conducted additional 2×4 ANOVAs for each variable based on a better-matched sub-group of successful abstainers and continuing smokers. Since pre-baseline salivary cotinine levels were shown to be the single most important clinical predictor of abstinent status in this sample (withdrawal symptoms, mood or dependence as assessed by the FTND were not significant predictors) [35], we have used this variable as a basis for matching. Thus a cut-off of 330 ng/ml was employed which resulted in the loss of three successful abstainers who were outliers at the high end, and eleven continuing smokers. These additional sub-analyses based on 29 quitters and 20 smokers matched for salivary cotinine level (quitters mean: 189.5; smokers mean: 179.5; t < 1, ns) are also reported in brief to supplement the main findings.


Background and Demographic Information

Of the 145 participants who completed the baseline assessments [5], 107 were randomised to quit; of these 33, (31%) maintained cotinine-verified abstinence at all follow-ups. Of the 38 participants allocated to continue smoking, 31 (82%) attended all follow-ups. All analyses are based on these two subgroups. Some data were missing for some variables, usually due to calibration or technical problems. Thus, sample sizes vary between analyses, from 26 to 33 abstainers and 25 to 31 continuing smokers.

Baseline (acute abstinence) scores for the 33 successful abstainers vs. the 31 continuing smokers were compared for all clinical and experimental variables via independent samples t-tests (and chi-square for sex ratio). The groups did not differ in sex ratio, age, years of education, number of cigarettes smoked per day, dependence (FTND), pre-baseline salivary cotinine levels, or any of the experimental variables (see Table 1).

Table 1
Means and (SD) for smoking-related, clinical and experimental variables assessed at baseline (acute abstinence) for abstainers and continuing-smokers

Clinical Variables

Withdrawal symptoms

Mean scores are shown in Figure 1.

Figure 1
Withdrawal symptoms scores (MPSS) on each assessment occasion for quitters and continuing smokers. Error bars are +/− 1SE

There was a significant decline in symptom severity from baseline (acute abstinence) to one week (F1,61 = 8.0, p < 0.01), this being more pronounced in the continuing smokers (GROUP × OCCASION: F1,61 = 4.4, p < 0.05). From one week to one month, a significant GROUP × OCCASION interaction (F1,61 = 4.4, p < 0.05) reflects a continued improvement in the abstainers versus a slight worsening in the continuing smokers. Symptoms remained stable from one to three months (no main effect of OCCASION nor an interaction with GROUP: F1,61 < 1, ns, in both cases). The groups did not differ significantly in the severity of their symptoms at any individual follow-up (t62 < 1.5, ns, in all cases). The pattern of findings was unchanged when we repeated the analysis using the better matched sub-sample.

Desire to smoke

Subjective desire to smoke is shown in Figure 2.

Figure 2
Ratings of desire to smoke on each assessment occasion for quitters and continuing smokers. Error bars are +/− 1SE

The decline in scores from baseline to one week was significant (F1,62 = 12.5, p = 0.001) and similar in both groups (no OCCASION × GROUP interaction: F1,62 < 1, ns). A further significant decline from a week to a month (F1,62 = 19.7, p < 0.001) was qualified by a significant GROUP × OCCASION interaction (F1,62 = 4.1, p < 0.05) with abstainers’ scores reducing more. There was no overall further reduction from one to three months, nor any interaction with GROUP (F1,62 < 1, ns, in both cases).

Abstainers’ scores were lower than those of the continuing smokers at all follow-up points; this difference was just short of significance at one week (t62 = −1.95, p < 0.06) but highly significant at both one and three months (t62 = 4.2 and 5.2, p < 0.001). The pattern of findings was unchanged when we repeated the analysis using the better matched sub-sample.

HADS anxiety

Anxiety scores are shown in Figure 3.

Figure 3
HADS Anxiety scores on each assessment occasion for quitters and continuing smokers. Error bars are +/− 1SE

ANOVA confirmed a significant reduction from baseline to one week (OCCASION: F1,61 = 5.7, p = 0.02) with no GROUP × OCCASION interaction (F1,61 < 1, ns). There was, however, a significant GROUP × OCCASION interaction from one week to one month (F1,61 = 4.9, p < 0.05) with abstainers showing a further reduction in anxiety but continuing smokers an increase. There was no significant change from one to three months (neither a main effect nor interaction: F1,61 < 1, ns).

Although the graph suggests that anxiety was higher in abstainers than continuing smokers at one week and vice versa at a month, the groups did not differ significantly at any follow-up point (t62 < 1, ns, in all cases).

These findings were essentially replicated in the better-matched sample, although the GROUP × OCCASION interaction from one week to one month now fell short of significance (F1,46 = 2.78, ns)

HADS depression

These scores are shown in Figure 4.

Figure 4
HADS depression scores on each assessment occasion for quitters and continuing smokers. Error bars are +/− 1SE

Mood improved significantly from baseline to one week (F1,62 = 7.7, p < 0.01) and this did not interact with GROUP (F1,62 < 1, ns).

A significant GROUP × OCCASION interaction from one week to one month (F1,62 = 6.5, p = 0.01), reflects an improvement in the abstainers but if anything a worsening in the continuing smokers. At this point, abstainers were significantly less depressed than continuing smokers (t62 = 2.1, p < 0.05). From one to three months there was neither a main effect of OCCASION nor a GROUP × OCCASION interaction (F1,62 < 1, ns, in both cases), though slight changes meant that they no longer differed significantly at this point (t62 < 1, ns).

Analyses using the better-matched sample of abstainers and continuing smokers again replicated these findings although the main effect of OCCASION from baseline to one week now fell short of significance (F1,47 = 2.17, ns)

Reward Motivation

SHAPS Anhedonia

Anhedonia scores are shown in Figure 5.

Figure 5
SHAPS anhedonia scores on each assessment occasion for quitters and continuing smokers (high score = greater anhedonia). Error bars are +/− 1SE

There was a significant improvement in hedonic tone (i.e. a reduction in SHAPS anhedonia scores) from baseline to one week (F1,59 = 4.9, p < 0.05), not qualified by an interaction with GROUP (F1,59 < 1, ns). There was no subsequent change (all main effects and interactions: F1,59 < 1, ns). At no time point did the two groups differ significantly from each other (t59 < 1, ns, in all cases).

Analysis of the smaller, better-matched sample revealed a similar pattern of results although the significant improvement from baseline to one week was now lost (F1,44 = 1.7, ns).

CARROT Reward Responsivity

Reward responsivity increased significantly from baseline to one week (F1,59 = 3.87, p = 0.05), with no GROUP × OCCASION interaction (F1,59 < 1, ns). There were no further changes across consecutive points (F1,59 < 1, ns, for both main effects and interactions), and at no follow-up did the two groups differ from each other (t59 < 1, ns, in all cases; see Figure 6).

Figure 6
Reward Responsivity scores on the CARROT on each assessment occasion for quitters and continuing smokers. Error bars are +/− 1SE

The same pattern of findings emerged in the better-matched sample but again, the improvement from baseline to one week now fell short of significance (F1,45 = 1.0, ns).

Attentional bias towards appetitive words (Stroop)

There was neither a significant main effect of OCCASION, nor an OCCASION × GROUP interaction, for the contrasts between any two consecutive occasions (F1,61 < 1, ns, in all cases; Table 2). The pattern of findings was unchanged when we repeated the analysis using the better matched sub-sample.

Table 2
Means and (SD)s for the ‘interference index’ (pleasure – neutral errors) on the Stroop task and motor errors on the Continuous Performance Task (CPT)

Response Inhibition

Oculomotor (antisaccade) task

Accuracy fluctuated markedly from one occasion to the next (see Figure 7). An improvement from acute abstinence to one week was significant (F1,50 = 10.9, p < 0.01) and greater in the continuing smokers (OCCASION × GROUP: F1,50 = 6.1, p < 0.02). A subsequent decline in accuracy between one week and one month was also significant (F1,50 = 4.1, p < 0.05) and did not interact with GROUP (F1,50 < 1, ns). There was a near-significant improvement from one to three months (F1,50 = 3.4, p = 0.07), again not interacting with GROUP (F1,50 < 1, ns). At no individual follow-up did the groups differ significantly from each other (t50 < 1, ns, in each case). Given the complexity of this pattern, scores at baseline were contrasted directly with those at three months, revealing a significant GROUP × OCCASION interaction (F1,55 = 6.1, p < 0.05) in which continuing smokers had improved highly significantly (t27 = 4.0, p <0.0001) whilst abstainers had not (t28 < 1, ns).

Figure 7
Antisaccade percentage correct on each assessment occasion for quitters and continuing smokers. Error bars are +/− 1SE

Analyses of the smaller, better-matched groups again revealed a significant improvement from acute abstinence to one week (F1,36 = 4.0, p < 0.05) whilst all other significant main effects and interactions now fell short of significance (F1,36 < 2.5, ns in all cases). However, the critical interaction from baseline to 3 months remained significant (F1,36 = 4.11, p < 0.05).

CPT motor errors

There were no main effects of OCCASION nor any GROUP × OCCASION interactions in the full, (F1,50 < 1, ns, in all cases; mean scores given in Table 2) or the better-matched, sub-sample.


Consistent with previous reports [17-19], self-reported withdrawal symptoms, anxiety and depression steadily improved over one month, whilst in continuing smokers they remained relatively stable across three months. Anxiety and depression scores were well within the ‘normal’ (non-clinical) range for both groups even during acute abstinence (baseline).

Abstainers’ marked decline in desire to smoke contrasted with the stability shown by continuing smokers’ across the three follow-ups. This profile is consistent Gilbert et al.'s findings that craving dropped steadily over the first month of quitting, differing statistically from the scores of continuing smokers by days 16−22 [36]. In the present study ratings of desire to smoke, mood and physical symptoms were made towards the end of the one-hour testing session; thus although continuing smokers had smoked immediately prior to the session they may have began to experience withdrawal by this point. Since participants reported smoking an average of 18.5 cigarettes per day (just over one per waking hour), their ratings within the session are likely to correspond to their experience at many points during a normal day.

Both abstainers’ and continuing smokers’ SHAPS anhedonia scores were lower at the one-week follow-up than during acute abstinence, and then remained stable to 3 months. The two groups did not differ at any point, and their mean scores fell within the normal range on all occasions. Pomerleau et al. [37] found self-reported anhedonia in ex-smokers (abstinent for 6 months or more) to be comparable with that in current smokers; both groups were more anhedonic than never-smokers. Thus although the present data suggest that any initial abstinence-related decline in hedonic tone rapidly recovers to the levels smokers achieve by smoking, in the absence of a matched group of non-smokers it is unclear to what extent it truly normalises.

Turning to reward motivation, whilst acute abstinence was characterised by lower baseline reward responsivity on the CARROT, this improved equally in the two groups by one week. Since performance in the continuing smokers was presumably enhanced by their recent nicotine use (consistent with our previous experimental findings [3-5]), the parallel improvement by the abstainers is therefore consistent with natural recovery. However practice/familiarity effects may also have contributed to the observed improvements in both groups.

With regard to attentional bias to pleasure-related words, there was little change in either abstainers or continuing smokers. In fact, there was no evidence that acute abstinence reduced attentional bias to pleasure versus neutral words in the subgroup of successful quitters described here, contrasting with our findings in the larger sample of 145 smokers [5]. This may reflect the lower statistical power yielded by this smaller sample, or alternatively a relative lack of motivational blunting during acute abstinence in smokers who are able to maintain prolonged abstinence. However it is notable that this same subgroup did exhibit diminished reward responsivity on the CARROT during acute abstinence.

Finally, abstainers showed no improvement on two indices of response inhibition (antisaccade accuracy and motor errors on the continuous performance task [CPT). Although neither group showed a change in CPT errors over time, continuing smokers did show improved accuracy on the antisaccade task once they had resumed smoking reflecting our previous finding [8]. Thus deficits in one index of inhibitory control – oculomotor response inhibition - do not appear to recover across three months of abstinence. These findings parallel Neuhaus et al's observation of abnormally low activation of frontal regions in long-term abstainers, [16] and are consistent with the existence of long-term deficits in response inhibition. These may reflect underlying neural dysfunctions which predate regular smoking or which are acquired during the course of regular smoking which fail to recover within the first few months of cessation. In either event, it could be an indicator of susceptibility to relapse, either because it correlates with a difficulty in inhibiting habitual smoking behaviour, or because smokers smoke in part to increase control over other their impulsive tendencies. Interventions to aid smoking cessation might therefore usefully focus on strategies for enhancing inhibitory control over the longer-term as well as in the initial stages of abstinence.

This study is not without its limitations. First, although an impressive one-third of smokers who were allocated to the quit group managed to abstain for 3 months, this nevertheless resulted in a fairly modest sample size of only 33 abstainers. Second, given that two-thirds of those allocated to the quit group subsequently relapsed, introduces the possibility that the self-selected abstainers showed reduced severity of impairment during acute abstinence. Nevertheless, we have shown in this sample that withdrawal symptoms, mood and dependence (on the FTND) did not significantly predict relapse whilst pre-quit salivary cotinine level did [35]. That our supplementary sub-analysis of successful abstainers and continuing smokers matched for cotinine levels confirmed the results of the full sample, affords us greater confidence in these findings. Third, it is possible that this group of successful abstainers had better emotional regulation ability for genetic or other reasons, or experienced fewer environmental stressors during abstinence, both of which were not assessed here.

Overall, the findings tentatively suggest that appetitive processes and related affective states do improve over three months of abstinence in those smokers who are able to remain nicotine-free whilst response inhibition may not. Nevertheless, the sample size and findings remain modest and should be treated with caution until they can be replicated in a larger and better matched sample.


This research was funded by the National Institute of Drug Abuse (NIDA); grant code 3527427).


1. Hughes JR, Higgins ST, Hatsukami D. Effects of abstinence from tobacco: A critical review. In: Kozlowski LT, Annis HM, Cappel HD, Glaser FB, Goodstadt MS, Israel Y, Kalant H, Sellers EM, Vingilis ER, editors. Res Ad Alcohol Drug probl. Vol. 10. Plenum; New York: 1990. pp. 317–398.
2. West R, Hajek P, Belcher M. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med. 1989;19:981–985. [PubMed]
3. Al-Adawi S, Powell J. The influence of smoking on reward responsiveness and cognitive functions: A natural experiment. Addiction. 1997;92:1773–1782. [PubMed]
4. Powell JH, Dawkins L, Davis R. Smoking, reward responsiveness, and response inhibition: Tests of an incentive motivational model. Biol Psychiatry. 2002;51:151–163. [PubMed]
5. Dawkins L, Powell JH, West R, Powell J, Pickering A. A double-blind placebo controlled experimental study of nicotine: I effects on incentive motivation. Psychopharmacology. 2006;189:355–367. [PubMed]
6. Powell JH, Tait S, Lessiter J. Cigarette smoking and attention to signals of reward and threat in the Stroop paradigm. Addiction. 2002;97:1163–1170. [PubMed]
7. Dawkins L, Acaster S, Powell JH. The effects of smoking and abstinence on experience of happiness and sadness in response to positively-valenced, negatively-valenced and neutral film clips. Addict Behav. 2007;32:425–431. [PubMed]
8. Dawkins L, Powell JH, West R, Powell J, Pickering A. A double-blind placebo controlled experimental study of nicotine: II effects on response inhibition and executive functioning. Psychopharmacology. 2007;190:457–467. [PubMed]
9. Pettiford J, Kozink RV, Lutz AM, Kollins SH, Rose JE, McClernon J. Increases in impulsivity following smoking abstinence are related to baseline nicotine intake and boredom susceptibility. Addict Behav. 2007;32:2351–7. [PMC free article] [PubMed]
10. Edginton T, Rusted JM. Separate and combined effects of scopolamine and nicotine on retrieval-induced forgetting. Psychopharmacology. 2003;70:351–7. [PubMed]
11. Shiffman S, Patten C, Gwaltney C, Paty J, Gnys M, Kassel J, Hickcox M, Waters A, Balabanis M. Natural history of nicotine withdrawal. Addiction. 2006;101:1822–1832. [PubMed]
12. Gilbert DG, McClernon J, Rabinovich NE, Sugai C, Plath LC, Asgaard G, Zuo Y, Huggenvik J, Botros N. Effects of quitting smoking on EEG activation and attention last for more than 31 days and are more severe with stress, dependence, DRD2 A1 allele, and depressive traits. Nicotine and Tobacco Research. 2004;6:249–267. [PubMed]
13. Bickel WK, Odum AL, Madden GJ. Impulsivity and cigarette smoking: delay discounting in current, never, and ex-smokers. Psychopharmacology. 1999;146:447–454. [PubMed]
14. Munafo M, Mogg K, Roberts S, Bradley BP, Murphy M. Selective processing of smoking-related cues in current smokers, ex-smokers and never-smokers on the modified Stroop task. J Psychopharmacol. 2003;17:310–316. [PubMed]
15. Ernst M, Matochik JA, Heishman SJ, Van Horn J, Jons PH, Henningfield JE, London ED. Effect of nicotine on brain activation during performance of a working memory task. Proc Natl Adad Sci USA. 2001;98:4728–4733. [PubMed]
16. Neuhaus A, Bajbouj M, Kienast T, von Haebler D, Winterer G, Gallinat J. Persistent dysfunctional frontal lobe activation in former smokers. Psychopharmacology. 2006;186:191–200. [PubMed]
17. Hughes JR, Hatsukami D. The nicotine withdrawal syndrome: a brief review and update. Int J Smoking Cessation. 1992;1:21–6.
18. Cummings KM, Giovino G, Jaen C, Emrich LJ. Reports of smoking withdrawal symptoms over a 21-day period of abstinence. Addict Behav. 1985;10:373–381. [PubMed]
19. Parrott AC. Smoking cessation leads to reduced stress: But why? Int J Addictions. 1995;30:1509–1516. [PubMed]
20. Alessi SM, Badjer GJ, Higgins T. An experimental examination of the initial weeks of abstinence in cigarette smokers. Exp Clin Psychopharm. 2004;12:276–287. [PubMed]
21. Gilbert DG, McClernon J, Rabinovich NE, Plath LC, Masson CL, Anderson AE, Sly KF. Mood disturbance fails to resolve across 31 days of cigarette abstinence in women. J Consult Clin Psychol. 2002;70:142–152. [PubMed]
22. Gilbert DG, Zuo Y, Browning RA, Shaw TM, Rabinovich NE, Gilbert-Johnson AM, Plath L. Platelet monoamine oxidase B activity changes across 31 days of smoking abstinence. Nicotine Tob Res. 2003;5:813–819. [PubMed]
23. McCarthy DE, Piasecki TM, Fiore MC, Baker TB. Life before and after quitting smoking: An electronic diary study. J Abnorm Psychol. 2006;115:454–466. [PubMed]
24. Piasecki TM, Fiore MC, Baker TB. Profiles in discouragement: Two studies of variability in the time course of smoking withdrawal symptoms. J Abnorm Psychol. 1998;107:238–251. [PubMed]
25. Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Smoking withdrawal dynamics. I. Abstinence distress in lapsers and abstainers. J Abnorm Psychol. 2003;112:3–13. [PubMed]
26. Gilbert DG, McClernon FJ. A smoke cloud of confusion. Am Psychol. 2000;55:1158–1159. [PubMed]
27. Jarvis MJ, Pedoe H, Feyerabend C, Vesey C, Saloojee Y. Comparison of tests used to distinguish smokers from non-smokers. Am J Public Health. 1987;77:1435–1438. [PubMed]
28. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addiction. 1991;86:1119–1127. [PubMed]
29. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361–370. [PubMed]
30. West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. Psychopharmacology. 2004;177:195–199. [PubMed]
31. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone: The Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167:99–103. [PubMed]
32. Fukushima J, Fukushima K, Miyasaka K, Yamashita I. Voluntary control of saccadic eye movement in patients with frontal cortical lesions and Parkinsonian patients in comparison with that in schizophrenics. Biol Psychiatry. 1994;36:21–30. [PubMed]
33. Clementz BA, McDowell JE, Zisook S. Saccadic system functioning among schizophrenia patients and their first degree biological relatives. J Abnorm Psychol. 1994;103:277–287. [PubMed]
34. Dougherty DM, Moeller FG, Steinberg JL, Marsh DM, Hines SE, Bjork JM. Alcohol increases commission error rates for a continuous performance test. Alcohol Clin Exp Res. 1999;23:1342–1351. [PubMed]
35. Powell JH, Dawkins L, West R, Powell J, Pickering A. Relapse to smoking during unaided cessation: clinical, cognitive and motivational predictors. Paper presented at the Society for the Study of Addiction, Annual Symposium. 2008
36. Gilbert DG, McClernon FJ, Rabinovich NE, Plath LC, Jensen RA, Meliska CJ. Effects of smoking abstinence on mood and craving in men: influences of negative-affect-related personality traits, habitual nicotine intake and repeated measurements. Pers Indiv Differ. 1998;25:399–423.
37. Pomerleau CS, Zucker AN, Steward AJ. Patterns of depressive symptomatology in women smokers, ex-smokers and never smokers. Addict Behav. 2003;28:575–582. [PubMed]